Jacob Fund, a mutual fund company, recently released its third-quarter 2025 investor letter, showcasing the continued market recovery and new all-time highs in major equity indexes. The finalized tariffs had limited economic impact, stabilizing the market and refocusing investors on fundamentals. The fund foresees a new productivity cycle that will enhance profit margins and earnings growth by keeping labor markets subdued. Focus remains on companies poised for earnings growth and improved valuation multiples, anticipating further asset price increases in the near-term.
One of the highlighted stocks in the investor letter is Omeros Corporation (NASDAQ:OMER), a clinical-stage biopharmaceutical company. With a one-month return of 64.39% and shares down 4.66% over the last 52 weeks, Omeros Corporation closed at $10.85 per share on December 05, 2025, with a market capitalization of $769.27 million.
The Jacob Fund added Omeros Corporation as one of its new positions in the quarter, citing the company’s focus on complement-related diseases and immunology. Omeros’ latest-stage product, Narsoplimab, a monoclonal antibody, is awaiting FDA approval for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. The fund sees strong approval chances and a favorable risk/reward ratio for Omeros, which is also in talks for a potential partnership to address balance sheet concerns.
While Omeros Corporation is not among the 30 most popular stocks among hedge funds, 14 hedge fund portfolios held the stock at the end of the third quarter. The fund acknowledges Omeros Corporation’s investment potential but believes that certain AI stocks offer greater upside potential with less downside risk. For those seeking an undervalued AI stock with significant potential from Trump-era tariffs and the onshoring trend, the fund recommends checking out their report on the best short-term AI stock.
In conclusion, Jacob Fund’s third-quarter 2025 investor letter highlights Omeros Corporation as a promising investment opportunity in the biopharmaceutical sector. With a focus on companies positioned for earnings growth and improved valuation multiples, the fund remains optimistic about the market’s trajectory in the coming months. Investors can explore the fund’s top 5 holdings for further insights into its investment strategy for 2025.
